It has been recently revealed in a report that a new drug for sarcomas has been approved by the Food and Drug Administration. This drug has been made by the drug form GlaxoSmithKline and is made for the treatment of a rare form of cancer.
There were studies conducted that revealed that the drug was capable of stopping the growth of tumor in the patients for a three month period. It was further added that the drug was tested for authenticity by the agency, and it was found that the patients suffering from this rare form of cancer actually tended to live longer due to this drug.
This type of tumor usually forms in the muscles, fat and the bones of the person. There are only few options for treatment of the same. This is what makes it all the more important to form drugs that actually work for the people in need.
“It's pretty soft data that we have in terms of measured responses. Everyone who treats sarcoma has been waiting for a noncytotoxic agent that has some benefits. But lack of robust response rate wouldn't dissuade me given the PFS”, revealed panelist Deborah Armstrong, MD, an oncologist at the Johns Hopkins University School of Medicine.
There is need for further research and development for making more worthy options for the treatment of this rare sort of disease. It remains to be seen how effective this drug is and how much it will affect people in the time to come. It needs to be seen how many people can be benefitted with the help of this novel drug. It shall be out for patients in a short time, as soon as it gets all the required approvals.
Good News USA
- Vodafone NZ’s new ‘Red Home’ packages will offer UFB and 150 TV channels
- Vodafone NZ’s full-year profit plunged by more than two-thirds to $56 million
- Vodafone adding 34 European countries to ‘AU$5 per day’ international roaming option
- Telstra launches its new ‘Every Day Connect Data Share Packages’
- Voyager signs “multimillion-dollar deal” with submarine cable group Hawaiki